Flecainide for the treatment of chronic neuropathic pain: A phase II trial eastern cooperative oncology group study E1Z95

Palliative Medicine

Volumn 21, Issue 8, 2007, Pages 667-672

  Von Gunten, Charles F ^a,i   Eappen, Sarah ^b   Cleary, James Francis ^c   Taylor IV, Samuel G ^d   Moots, Paul ^e   Regevik, Nina ^f   Cleeland, Charles ^g   Cella, David ^h  

^a NORTHWESTERN UNIVERSITY   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c UNIVERSITY OF WISCONSIN MADISON   (United States)

^d ADVOCATE ILLINOIS MASONIC MEDICAL CENTER   (United States)

^e VANDERBILT UNIVERSITY   (United States)

^f Raritan Bay Medical Center   (United States)

^g UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^h EVANSTON NORTHWESTERN HEALTHCARE   (United States)

ⁱ San Diego Hospice & Palliative Care Center for Palliative Studies   (United States)

Author keywords

AIDS; Cancer; Flecainide; Neuropathic; Pain

Indexed keywords

ANTINEOPLASTIC AGENT; FLECAINIDE; HORMONE; NARCOTIC ANALGESIC AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AGED; ARTICLE; CANCER HORMONE THERAPY; CANCER IMMUNOTHERAPY; CANCER PAIN; CHRONIC PAIN; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; HUMAN; MALE; MALIGNANT NEOPLASTIC DISEASE; MULTICENTER STUDY; NEUROPATHIC PAIN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; RATING SCALE; TREATMENT DURATION;

ADULT; AGED; ANALGESICS; FEMALE; FLECAINIDE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; NEURALGIA; PAIN; PAIN MEASUREMENT; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 38549128123     PISSN: 02692163     EISSN: None     Source Type: Journal    
DOI: 10.1177/0269216307083031     Document Type: Article

References (30)

1. McDonald AA, Portenoy RK. How to use antidepressants and anticonvulsants as adjuvant analgesics in the treatment of neuropathic cancer pain. J Support Oncol 2006; 4: 43052.
2. Ferris FD, von Gunten CF, Emanuel LL. Ensuring competency in end-of-life care: controlling symptoms. BMC Palliat Care 2002; 1: 5.
3. Stjernsward J, Teoh N. The cancer pain relief program of the World Health Organization. Palliat Med 1989; 4: 1-3.
4. Ventafridda V, Stjernsward J. Pain control and the World Health Organziation analgesic ladder. JAMA 1996; 275: 835-6.
5. Fallon M, McConnell S. The principles of cancer pain management. Clin Med 2006; 2: 136-9.
6. IASP Subcommittee on Taxonomy Classification of Chronic Pain. Pain 1986; 3(Suppl): S1-225.
7. Gilron I, Watson CP, Cahill CM, Moulin DE. Neuropathic pain: a practical guide for the clinician. CMAJ 2006; 175(3): 265-75.
8. Iwane T, Maruyama M, Matsuki M, Ito Y, Shimoji K. Management of intractable pain in adiposis dolorosa with intravenous administration of lidocaine. Anesth Analg 1976; 55(2): 257-9.
9. Challapalli V, Tremont-Lukats IW, McNicol ED, Lau J, Carr DB. Systemic administration of local anesthetic agents to relieve neuropathic pain. Cochrane Database Syst Rev 2005; 4: CD003345.
10. Thomas J, Kronenberg R, Cox MC, Naco GC, Wallace M, von Gunten CF. Intravenous lidocaine relieves severe pain: results of an inpatient hospice chart review. J Palliat Med 2004; 7(5): 660-7.
11. Ferrini R. Parenteral lidocaine for severe intractable pain in six hospice patients continued at home. J Palliat Med 2000; 3(2): 193-200.
12. Ferrini R, Paice JA. How to initiate and monitor infusional lidocaine for severe and/or neuropathic pain. J Support Oncol 2004; 2(1): 90-4.
13. Working Group on Arrhythmias. The Sicilian Gambit: a new approach to the classification of antiarrhythmic drugs based on their actions on arrhythmogenic mechanisms. Circulation 1991; 84: 1831-51.
14. Sloan P, Basta M, Storey P, von Gunten C. Mexiletine as an adjuvant analgesic for the management of neuropathic cancer pain. Anesth Analg 1999; 89: 760-1.
15. Dejgard A, Petersen P, Kastrup J. Mexiletine for treatment of chronic painful diabetic neuropathy. Lancet 1988; 2(9): 9-11.
16. Dunlop R, Davis RJ, Hockley J, Turner P. Analgesic effects of oral flecainide. Lancet 1988; 1(8582): 420-1.
17. Mendoza T, Mayne T, Rublee D, Cleeland C. Reliability and validity of a modified Brief Pain Inventory short form in patients with osteoarthritis. Eur J Pain 2006; 10: 353-61.
18. National Cancer Institute Common Toxicity Criteria. http://ctep.cancer.gov/forms/CTCv20_4-30-992.pdf (Accessed 24 July 2006).
19. Hrobjartsson A, Gotzxche PC. Is the placebo powerless? An analysis of clinical trials comparing placebo with no treatment. N Engl J Med 2001; 344: 1594-602.
20. Echt DS, Liebson PR, Mitchell LB et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo: the cardiac arrhythmia suppression. Trial N Engl J Med 1991; 324: 781-8.
21. Marriott HJL, Conover MB. Advanced concepts in arrhythmias, second edition, CV Mosby, 1989: 174.
22. Working Group on Arrhythmias. The Sicilian Gambit: a new approach to the classification of antiarrhythmic drugs based on their actions on arrhythmogenic mechanisms. Circulation 1991; 84: 1831-51.
23. Brosen K. Recent developments in hepatic drug oxidation: implications for clinical pharmacokinetics. Clin Pharmacokinet 1990; 18: 220-39.
24. Brosen K, Gram LF. Clinical significance of the sparteine/debrisoquine oxidation polymorphism. Eur J Clinical Pharmacol 1989; 36: 537-47.
25. Wallace MS, Dyck JB, Rossi SS, Yaksh TL. Computer-controlled lidocaine infusion for the evaluation of neuropathic pain after peripheral nerve injury. Pain 1996; 66(1): 69-77.
26. Wallace MS, Laitin S, Licht D, Yaksh TL. Concentration-effect relations for intravenous lidocaine infusions in human volunteers: effects on acute sensory thresholds and capsaicin-evoked hyperpathia. Anesthesiology 1997; 86(6): 1262-72.
27. Wallace MS, Lee J, Sorkin L, Dunn JS, Yaksh T, Yu A. Intravenous lidocaine: effects on controlling pain after anti-GD2 antibody therapy in children with neuroblastoma-a report of a series. Anesth Analg 1997; 85(4): 794-6.
28. Wallace MS, Ridgeway BM, Leung AY, Gerayli A, Yaksh TL. Concentration-effect relationship of intravenous lidocaine on the allodynia of complex regional pain syndrome types I and II. Anesthesiology 2000: 92(1): 75-83.
29. MacMahon S, Collins R, Peto R, Koster RW, Yusuf S. "Effects of prophylactic lidocaine in suspected acute myocardial infarction. An overview of results from the randomized, controlled trials." JAMA 1988; 260(13): 1910-6.
30. Brookoff D. Chronic pain: a new disease? Hosp Pract 2000; 35: 45-52, 59.